The current process is dependent on the size and nature of the deployment.
If we have small numbers of people going off as UN military observers, for example, they would have a briefing with a preventative medicine technician about the risks of the region they're going to, which would include the risk of malarial infection, if it were there. Then those small groups of individuals would have a face-to-face encounter with a physician or a pharmacist at which there would be discussion about all of the options available in the region to which they are going to combat malaria.
That discussion would include the medications available, the advantages, the dosing schedules of each of those types of available medications, as well as a discussion of the risks of adverse effects and the types of adverse effects they might experience with the medications being considered. Then, in a discussion with them about what their preferences would be with respect to advantages and disadvantages and the potential for adverse effects, they'll make a decision about which medication to go with.
If there are larger groups, there will probably be a larger presentation to a company-size or platoon-size group given by a medical provider, probably a pharmacist. They wouldn't have that individual session up front, although they would fill in a questionnaire that identifies the risk factors we need to consider for each of the medications, and there would then be a review of what they report with respect to their risk factors and the antimalarial they might want to select. We will then have them sit down with a health care provider to receive these medications.